Dickson Thian is VP of Investments at Xora, where he has played a key role in developing the firm’s early portfolio. Dickson currently serves as Interim Chief of Staff and Board Observer at Amperesand, where he was instrumental in efforts to incubate and launch the company. During his time at Xora, he has been on the deal team for Aether Fuels, Celestial AI, Cosmos Innovation, Hyperlight, SpeQtral, Summit Nanotech and Talus.
Prof Loh Xian Jun completed his basic and postgraduate studies at the National University of Singapore. As a polymer chemist by training, he is currently the Executive Director of A*STAR Institute of Materials Research and Engineering ( A*STAR IMRE ). He is concurrently an Adjunct Professor in the National University of Singapore and Nanyang Technological University. As a pioneer and recognized global expert in the area of biodegradable thermogels, he is highly knowledgeable in developing these materials for various applications s
Fong Saik Hay is currently a corporate advisor with a Temasek Deep Tech Fund, Xora Innovation.
He is also helping 3G&S nurture Grimes Decarbonizing Technology Platform anchoring her in Singapore.
Dr. Chueh Loo POH is an Associate Professor with the Department of Biomedical Engineering, College of Desing and Engineering, at National University of Singapore (NUS). He is Director of NUS Biofoundry and a Team PI at National Centre for Engineering Biology (NCEB), Singapore. He is also deputy director of SINERGY, Singapore consortium for Synthetic Biology. His research interests in Synthetic Biology focuses on reprogramming microbes for health and sustainability.
Dr. Rosemary Tan is CEO of Leyden Labs Asia, a subsidiary of Leyden Laboratories B.V., which develops intranasal antibody therapies for broad protection against respiratory viruses. Prior to this, she led CoV Biotechnology, focused on coronavirus vaccines and antibodies, which was acquired by Leyden Labs in 2024. Earlier in her career, she founded Veredus Laboratories, a pioneer in diagnostic and bio-surveillance technologies which was acquired by Sekisui Chemical.
Dr Rajan Kalidindi is the Chief Commercial and Strategy Officer for GE HealthCare in ASEAN, Korea and ANZ region. With over two decades of experience across healthcare, innovation and commercial leadership, Rajan brings deep expertise in scaling technologies and building high-impact strategies. He previously led GE HealthCare Services and the Ultrasound business in ASEAN and held leadership roles across GE businesses and academic institutions. Before GE, Rajan was with NTU, supporting I
Mark Holst has over 20 years of experience with Shell working in oil & gas field development covering conventional, Enhanced Oil Recovery, on/offshore assets and operations in the Netherlands, Malaysia and Oman. Following an MBA with London Business School he joined the Upstream Strategy Group supporting the Senior Executive Leadership with the design and implementation of multiple portfolio, business and corporate level strategies.
A/Prof Cher Heng Tan graduated with MBBS (Singapore) and FRCR (UK). He completed his Abdominal Imaging Fellowship at MD Anderson Cancer Center and holds an Executive MBA from Insead. He is presently Senior Consultant with the Department of Diagnostic Radiology and Assistant Chairman Medical Board at Tan Tock Seng Hospital. He is concurrently Group Chief, Research and Innovation for NHG Health and Assistant Dean (Clinical Research) for the Lee Kong Chian School of Medicine.
Professor Reginald B.H. TAN is Executive Director at the Science and Engineering Research Council at A*STAR, and concurrently Professor at the Department of Chemical and Biomolecular Engineering at the National University of Singapore.
